名稱：重組人IFN-λ1/IL-29
Synonyms：Cytokine Zcyto21
Species：9
Accession：Q8IU54
GeneID：282618
Source：Escherichia coli.
Molecular Weight：Approximately 19.8 kDa, a single non-glycosylated polypeptide chain containing 181 amino acids.
Quantity：5μg/20μg/1000μg
AA Sequence：GPVPTSKPTT TGKGCHIGRF KSLSPQELAS FKKARDALEE SLKLKNWSCS SPVFPGNWDL RLLQVRERPV ALEAELALTL KVLEAAAGPA LEDVLDQPLH TLHHILSQLQ ACIQPQPTAG PRPRGRLHHW LHRLQEAPKK ESAGCLEASV TFNLFRLLTR DLKYVADGNL CLRTSTHPES T
Purity：> 97 % by SDS-PAGE and HPLC analyses.
Biological Activity：Fully biologically active when compared to standard. The ED50 as determined by an anti-viral assay using human HepG2 cells infected with encephalomyocarditis is less than 5 ng/ml, corresponding to a specific activity of > 2.0 × 105 IU/mg.
Physical Appearance：Sterile Filtered White lyophilized (freeze-dried) powder.
Formulation：Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4.
Endotoxin：Less than 1 EU/μg of rHuIFN-λ1/IL-29 as determined by LAL method.
Reconstitution：We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
Stability & Storage：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Reference：1. Miller EK, Hernandez JZ, Wimmenauer V, et al. 2012. Am J Respir Crit Care Med, 185: 508-16.
2. Li Y, Xie J, Xu X, et al. 2012. Protein Cell,
3. Jordan WJ, Eskdale J, Srinivas S, et al. 2007. Genes Immun, 8: 254-61.
4. Pekarek V, Srinivas S, Eskdale J, et al. 2007. Genes Immun, 8: 177-80.
5. Megjugorac NJ, Gallagher GE, Gallagher G. 2010. Blood, 115: 4185-90.
Background：IL-28A, IL-28B, and IL-29, also named interferon-λ2 (IFN-λ2), IFN-λ3, and IFN-λ1, respectively, are newly identified class II cytokine receptor ligands that are distantly related to members of the IL-10 family (11-13 % a.a. sequence identity) and the type I IFN family (15-19 % a.a. sequence identity). The expression of IL-28A, B, and IL-29 is induced by virus infection or double-stranded RNA. All three cytokines exert bioactivities that overlap those of type I IFNs, including antiviral activity and up-regulation of MHC class I antigen expression. The three proteins signal through the same heterodimeric receptor complex that is composed of the IL-10 receptor β (IL-10 Rβ) and a novel IL-28 receptor α (IL-28 Rα, also known as IFN-λR1). Ligand binding to the receptor complex induces Jak kinase activation and STAT1 and STAT2 tyrosine phosphorylation.